- Home
- STXS vs SLS Comparison
STXS vs SLS Comparison
Compare STXS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STXS | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 208.0M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | STXS | SLS |
|---|---|---|
| Price | $2.55 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 388.9K | ★ 11.1M |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,075,000.00 | N/A |
| Revenue This Year | $24.21 | N/A |
| Revenue Next Year | $29.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.62 | N/A |
| 52 Week Low | $1.54 | $0.85 |
| 52 Week High | $3.59 | $5.18 |
Technical Indicators
Market Signals| Indicator | STXS | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 69.48 |
| Support Level | $2.25 | $2.60 |
| Resistance Level | $2.48 | $5.18 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 63.34 | 65.63 |
Price Performance
Historical ComparisonAbout STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.